InMed Pharmaceuticals(US:INM)2019-09-16 17:50Company Overview - InMed Pharmaceuticals focuses on therapeutic applications of cannabinoids for diseases with high unmet medical needs[7] - The company is researching the therapeutic potential of rare cannabinoids, excluding THC & CBD[8, 11] - InMed has a biosynthesis manufacturing platform for producing cannabinoids[9] Pipeline and Market - INM-755 targets Epidermolysis Bullosa, addressing a market of 10.1 thousand people with a total market size of $1 billion[9] - INM-088 targets Glaucoma, addressing a market of 14.2 million people with a total market size of $6.2 billion[9] - INM-405 targets Orofacial Pain, addressing a market of 52.7 million people with a total market size of $4 billion[9] Financial Status - As of March 31, 2019, InMed had C$20.3 million (US$15.2 million) in cash equivalents and short-term investments[62] - As of August 29, 2019, InMed's market capitalization was C$62.0 million[63] - The company anticipates a cash runway into the second half of 2020[4] Biosynthesis Program - In 2018, InMed was awarded grants for biosynthesis: NSERC C$136,000 and NRC-IRAP C$500,000[22] - The company has signed contracts with the National Research Council in Montreal to optimize fermentation and scale-up process (USP) in E coli[22]